Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 16, 2024DiseasesOpen Access

Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAmanda Claudia SchuldeszRMRam Kiran MagantiRTRaluca Tudor

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Schuldesz et al. (2024) studied this question.

synapsesocial.com/papers/68e64883b6db6435875d9c7ahttps://doi.org/10.3390/diseases12060127
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long‐Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real‐World Longitudinal Study2026 · 1 citations
  2. 2A Retrospective, Single-Arm, Observational Study in Patients with Multiple Sclerosis in India Receiving Ocrelizumab Therapy for 1 Year2026
  3. 3A two-year single-site longitudinal assessment of brain and retinal atrophy in ocrelizumab-treated relapsing–remitting multiple sclerosis2026
  4. 4Ocrelizumab: a new milestone in multiple sclerosis therapy2018 · 142 citations
  5. 51ISG-016 Ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis in a national health system: a cost effectiveness analysis2024 · 1 citations